Share This! Tweet This! Recommend Us! Print Page

Current Cancer Trials

Find a Doctor
Find a Location

Participate in One of These Clinical Trials

Brain

RTOG 0834 

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial.

Protocol Summary

Consent Form - Password Protected

ALLIANCE A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Protocol Summary

Consent Form - Password Protected


Breast

SCCA 6628

A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targetd Therapy with Bevacizumab and Erlotinib

Protocol Summary

PH3-01

Prevention of Recurrence in Early Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTM Treatment (PRESENT)

Protocol Summary

ECOG 2108

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patents with Metastatic Breast Cancer

Protocol Summary

Consent Form - Password Protected


8093

Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Protocol Summary

SWOG 1007 (Quality of Life - Closed)

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

Protocol Summary

Consent Form (Step 1) - Password Protected

Consent Form (Step 2) - Password Protected


SWOG 1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy

Protocol Summary

Consent Form - Password Protected

NSABP B-47

A Randomized Phase III Trial of Adjuvant Therapy Comparing
Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

Protocol Summary

Consent Form - Password Protected

NSABP B-52

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation

Protocol Summary

Consent Form - Password Protected

NSABP B-51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected


Alliance A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected


SWOG 1202

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

Protocol Summary

Consent Form - Password Protected


14-002

Genomic markers in BREAST cancer:  sample acquisition for methods development and discovery


Gastrointestinal

CALGB 80702

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Protocol Summary

Consent Form - Password Protected


SWOG 0820

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Protocol Summary

Consent Form - Password Protected

RTOG 1010


A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Protocol Summary

Consent Form - Password Protected

CALGB 80802

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

Protocol Summary

Consent Form - Password Protected

SWOG 1201

A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer.

Protocol Summary

Consent Form - Password Protected

RTOG 0848


A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Protocol Summary

Consent Form - Password Protected


ECOG 2211

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Protocol Summary

Consent Form - Password Protected

ALLIANCE N1048

A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Protocol Summary

Consent Form - Password Protected


Genitourinary

RTOG 0534 

-Note:  QOL Closed-

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.

Protocol Summary

Consent Form - Password Protected

CALGB 90203

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

Protocol Summary

Consent Form - Password Protected


CALGB 70807

The Men's Eating and Living (MEAL) Study: A Randomized Trial of diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.

Protocol Summary

Consent Form - Password Protected


SWOG 1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Protocol Summary

Consent Form - Password Protected

SWOG 0931


EVEREST
:  Everolimus for Renal Cancer Ensuring Surgical Therapy, a Phase III Study 

Protocol Summary

Consent Form - Password Protected


ECOG 2810 

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Protocol Summary

Consent Form - Password Protected


Gynecologic

RTOG 0724

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.

Protocol Summary

Consent Form - Password Protected

RTOG 1203

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Protocol Summary

Consent Form - Password Protected

GOG 0277

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Protocol Summary

Consent Form - Password Protected


Head & Neck

ECOG 1311

A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Protocol Summary

Consent Form - Password Protected


Hematology

ECOG 1912

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Protocol Summary

Consent Form - Password Protected

REVEAL:  PRospective ObsErvational Study of Patients with Polycythemia VEra in US ClinicAL Practices

Protocol Summary

Consent Form - Password Protected


Lung

ALLIANCE A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Protocol Summary

Consent Form - Password Protected


ALLIANCE A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol Summary

Consent Form - Password Protected


ECOG 4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Protocol Summary

Consent Form - Password Protected


ECOG 5508

Randomized Phase III Study of Maintenance Therapy with Bevacizumab Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advance Non-Squamous NSCLC.

Protocol Summary

Consent Form - Password Protected


SCCA 7755 

A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Protocol Summary


SWOG 1400 (LUNG-MAP)

-Note:  Arm E Closed-

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Protocol Summary

Consent Form (Screening) - Password Protected

Consent Form (Arm A) - Password Protected

Consent Form (Arm B) - Password Protected

Consent Form (Arm C) - Password Protected

Consent Form (Arm D) - Password Protected


TH-CR-415 (THRESHOLD)

A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer

Protocol Summary


Lymphoma

PSOC 2502

A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)

Protocol Summary


Multiple Myeloma

ECOG-ACRIN E3A06

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Protocol Summary

Other

CLEE011XUS03

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors

Protocol Summary


FH 7159 (Limited Institutions)

Advanced PET/CT Imaging for Clinical Trials 


For more information and/or copies of protocols:

Contact Michelle Maxin-Wells by phone at 253-403-7193, or by email: michelle.maxin-wells@multicare.org